ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Return
4.95%
This Quarter Return
+13.07%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$246M
AUM Growth
-$60.8M
(-20%)
Cap. Flow
-$65.7M
Cap. Flow
% of AUM
-26.67%
Top 10 Holdings %
Top 10 Hldgs %
67.39%
Holding
78
New
29
Increased
8
Reduced
16
Closed
23
Top Buys
| 1 |
Merck
MRK
|
$14M |
| 2 |
Centene
CNC
|
$13.8M |
| 3 |
Sabra Healthcare REIT
SBRA
|
$5.43M |
| 4 |
Cigna
CI
|
$5.16M |
| 5 |
Elevance Health
ELV
|
$4.96M |
Top Sells
| 1 |
Humana
HUM
|
$15.9M |
| 2 |
Takeda Pharmaceutical
TAK
|
$14.3M |
| 3 |
Qiagen
QGEN
|
$13.1M |
| 4 |
Eli Lilly
LLY
|
$12.4M |
| 5 |
Baxter International
BAX
|
$11.9M |
Sector Composition
| 1 | Healthcare | 73.98% |
| 2 | Real Estate | 2.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
26
DELISTED
CATALENT, INC.
CTLT
| $1.59M | 0.64% |
35,265
-104,812
| -75% | -$4.72M |
|
|
SILK
27
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $1.58M | 0.64% |
+29,967
| New | +$1.58M |
|
28
HCA Healthcare
HCA
$97.2B
| $1.58M | 0.64% |
+6,595
| New | +$1.58M |
|
29
Healthpeak Properties
DOC
$12.3B
| $1.49M | 0.61% |
+59,578
| New | +$1.49M |
|
30
Terns Pharmaceuticals
TERN
$596M
| $1.38M | 0.56% |
+135,994
| New | +$1.38M |
|
31
Charles River Laboratories
CRL
$7.94B
| $1.36M | 0.55% |
+6,258
| New | +$1.36M |
|
32
Arrowhead Research
ARWR
$3.81B
| $1.14M | 0.46% |
+28,187
| New | +$1.14M |
|
33
BioAtla
BCAB
$28.4M
| $1.13M | 0.46% |
+136,382
| New | +$1.13M |
|
34
10x Genomics
TXG
$1.66B
| $1.11M | 0.45% |
+30,357
| New | +$1.11M |
|
35
Alnylam Pharmaceuticals
ALNY
$59.6B
| $1.09M | 0.44% |
+4,596
| New | +$1.09M |
|
|
GRTS
36
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $976K | 0.4% |
+282,935
| New | +$976K |
|
37
Thermo Fisher Scientific
TMO
$183B
| $875K | 0.36% |
+1,589
| New | +$875K |
|
38
Axsome Therapeutics
AXSM
$6.12B
| $869K | 0.35% |
+11,264
| New | +$869K |
|
39
Dentsply Sirona
XRAY
$2.83B
| $703K | 0.29% |
+22,088
| New | +$703K |
|
40
PTC Therapeutics
PTCT
$4.47B
| $683K | 0.28% |
+17,886
| New | +$683K |
|
41
Intellia Therapeutics
NTLA
$1.23B
| $572K | 0.23% |
+16,401
| New | +$572K |
|
|
42
Baxter International
BAX
$12.2B
| $561K | 0.23% |
11,008
-234,085
| -96% | -$11.9M |
|
|
IGMS
43
DELISTED
IGM Biosciences
IGMS
| $516K | 0.21% |
+30,320
| New | +$516K |
|
44
Actinium Pharmaceuticals
ATNM
$52.7M
| $486K | 0.2% |
+45,612
| New | +$486K |
|
45
89bio
ETNB
$1.27B
| $468K | 0.19% |
+36,784
| New | +$468K |
|
46
Iovance Biotherapeutics
IOVA
$771M
| $451K | 0.18% |
+70,655
| New | +$451K |
|
|
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
| $411K | 0.17% |
+21,041
| New | +$411K |
|
|
INBX
48
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $332K | 0.13% |
+13,485
| New | +$332K |
|
49
Maravai LifeSciences
MRVI
$337M
| $307K | 0.12% |
21,458
-1,251
| -6% | -$17.9K |
|
50
Biodesix
BDSX
$64.9M
| $286K | 0.12% |
124,430
-5,706
| -4% | -$13.1K |
|